Only in Titles

Search results for: Isotypes

paperclip

#33086191   // To Up

PDK2-enhanced glycolysis promotes fibroblast proliferation in thyroid-associated ophthalmopathy.

The study aimed to investigate the role of pyruvate dehydrogenase kinase (PDK) in regulating glycolysis and proliferation of perimysial orbital fibroblasts (pOFs) during the pathogenesis of thyroid-associated ophthalmopathy (TAO). EdU and BrdU incorporation assays were performed to examine cell proliferation. Lactate production and oxygen consumption assays were conducted to evaluate glycolysis. Real-time PCR was adapted to quantify PDK mRNA levels. Capillary Western immunoassay was adapted to quantify PDK2, Akt, pAkt308 and GAPDH in protein samples. The TAO pOFs exhibited stronger proliferation activity, higher intracellular lactate concentration, and lower oxygen consumption rate than the control pOFs. The PDK inhibitor dichloroacetic acid (DCA) dose-dependently suppressed the proliferation of both TAO and control pOFs. DCA reduced lactate production and promoted oxygen consumption in the TAO pOFs but showed no significant effects on glycolysis in the control pOFs. Among four PDK isotypes, PDK2 was overexpressed in the TAO pOFs. The potential PDK signaling mediator, cytoplasmic Akt, was more abundant in TAO pOFs than control pOFs. Knockdown of PDK2 resulted in lower lactate production, stronger oxygen consumption, weaker proliferation activity, and less cytoplasmic Akt in the TAO pOFs but showed no significant effects in the control pOFs. The Akt inhibitor MK2206 suppressed proliferation in both TAO and control pOFs, and lactate production was inhibited by MK2206 in the TAO OFs but not the control pOFs. To conclude, PDK2 overexpression enhances glycolysis and promotes proliferation via Akt signaling in the TAO pOFs. These findings yield insights that PDK2 is a potential therapeutic target for TAO treatment.
Ruiqi Ma, Lu Gan, Hui Ren, Andrew Harrison, Jiang Qian

2856 related Products with: PDK2-enhanced glycolysis promotes fibroblast proliferation in thyroid-associated ophthalmopathy.

100 μg100 ml.100μg25 ml.100μg

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#33071558   // To Up

Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG.

The 2019 Coronavirus disease (COVID-19) has been characterized as a pandemic, representing a serious global public health emergency. Serological tests have been proposed as reliable tools for detecting Coronavirus SARS-CoV-2 antibodies in infected patients, especially for surveillance or epidemiological purposes. The aim of this study is to evaluate the agreement between the IgM/IgG rapid assays, based on lateral flow immunochromatographic assay, and the fully automated 2019-nCoV IgM and IgG, based on chemiluminescence immunoassay.
Caterina Maria Gambino, Bruna Lo Sasso, Claudia Colomba, Rosaria Vincenza Giglio, Luisa Agnello, Giulia Bivona, Marcello Ciaccio

1757 related Products with: Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG.

1000 TESTS/0.65ml250tests1000 TESTS/0.25ml25 TESTS/0.25ml100 TESTS 96 Tests 0.1ml (1mg/ml)25ml 10025 Tests25 Tests100 Tests

Related Pathways

paperclip

#33069957   2020/10/09 To Up

Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform.

The 2019 SARS CoV-2 (COVID-19) pandemic has illustrated the need for rapid and accurate diagnostic tests. In this work, a multiplexed grating-coupled fluorescent plasmonics (GC-FP) biosensor platform was used to rapidly and accurately measure antibodies against COVID-19 in human blood serum and dried blood spot samples. The GC-FP platform measures antibody-antigen binding interactions for multiple targets in a single sample, and has 100% selectivity and sensitivity (n = 23) when measuring serum IgG levels against three COVID-19 antigens (spike S1, spike S1S2, and the nucleocapsid protein). The GC-FP platform yielded a quantitative, linear response for serum samples diluted to as low as 1:1600 dilution. Test results were highly correlated with two commercial COVID-19 antibody tests, including an enzyme linked immunosorbent assay (ELISA) and a Luminex-based microsphere immunoassay. To demonstrate test efficacy with other sample matrices, dried blood spot samples (n = 63) were obtained and evaluated with GC-FP, yielding 100% selectivity and 86.7% sensitivity for diagnosing prior COVID-19 infection. The test was also evaluated for detection of multiple immunoglobulin isotypes, with successful detection of IgM, IgG and IgA antibody-antigen interactions. Last, a machine learning approach was developed to accurately score patient samples for prior COVID-19 infection, using antibody binding data for all three COVID-19 antigens used in the test.
Nathaniel C Cady, Natalya Tokranova, Armond Minor, Nima Nikvand, Klemen Strle, William T Lee, William Page, Ernest Guignon, Arturo Pilar, George N Gibson

2314 related Products with: Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform.

96 tests100ug Lyophilized 100 UG 100ul 100 UG1 module100ug Lyophilized1 mg 100ul96 tests 100ul

Related Pathways

paperclip

#33059025   2020/10/12 To Up

Novel Mutations in TUBB8 Expand the Mutational and Phenotypic Spectrum of Patients with Zygotes Containing Multiple Pronuclei.

After fertilization, parental chromosomes decondense and form pronuclei. During these processes, germ cell genomes merge and give rise to the zygotic genome. Multiple pronuclei (MPN) formation is usually caused by polyspermic fertilization or oocyte-derived meiotic failure, and account for 15%-18% of cytogenetically abnormal cases among spontaneous abortions. However, pathogenic gene mutations responsible for human MPN formation still need to be identified. Tubulin β eight class VIII (TUBB8) is the major β-tubulin isotype that assembles the human oocyte spindle. In this study, we identified 3 novel heterozygous missense mutations (c.524 T>C [p.V175A], c.10_12delins CTT [p.I4L], and c.1045 G>A [p.V349I]) in TUBB8 that were associated with a new phenotype: MPN in zygotes after IVF or ICSI. These mutations were found in 3 independent female patients with infertility, and had experienced 2-3 failed in vitro fertilization (IVF)/ICSI attempts due to zygotic developmental arrest. These sites are evolutionarily conserved in primate TUBB8 genes as well as in other human β-tubulin isotypes, suggesting that they have important biochemical functions. This finding reveals previously unreported phenotypes caused by TUBB8 mutations and will be helpful for future genetic counseling of infertile patients with MPN.
Qianqian Sha, Wei Zheng, Xie Feng, Ruiying Yuan, Huiling Hu, Fei Gong, Liang Hu, Ge Lin, Xianghong Ou

1274 related Products with: Novel Mutations in TUBB8 Expand the Mutational and Phenotypic Spectrum of Patients with Zygotes Containing Multiple Pronuclei.

5mg

Related Pathways

paperclip

#33055354   // To Up

CONGENITAL HEMOLYTIC ANEMIA IN CHILDREN, FEATURES OF THE COURSE AND DIAGNOSIS. THE CLINICAL CASE.

We've reported a clinical case of congenital hemolytic anemia which was treated in Vinnitsa Regional Children's Hospital from newborn period until now. We've used complete blood count, biochemichal blood investigation, ultrasound investigation of the abdominal cavity in every hospitalization. Also IFA for TOXO IgG, IgM and G CMV, IgG HSV-6 IgG EBV (EBNA) and IgM EBV, study to hepatitis B and C viruses and HIV were made. There were checked levels of serum iron, ferritin, vitamin B 12 and folic acid in blood serum.
Veronika M Dudnyk, Tatyana H Korol, Hennadii M Rudenko, Kateryna V Khromykh, Maryna O Shalamai

2553 related Products with: CONGENITAL HEMOLYTIC ANEMIA IN CHILDREN, FEATURES OF THE COURSE AND DIAGNOSIS. THE CLINICAL CASE.

1

Related Pathways

paperclip

#33050892   2020/10/13 To Up

Characteristics of recovered COVID-19 patients with recurrent positive RT-PCR findings in Wuhan, China: a retrospective study.

Two months after the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, tens of thousands of hospitalized patients had recovered, and little is known about the follow-up of the recovered patients.
Tie-Jun Shui, Chao Li, Hong-Bing Liu, Xiaohua Chen, Bi-Ke Zhang

1143 related Products with: Characteristics of recovered COVID-19 patients with recurrent positive RT-PCR findings in Wuhan, China: a retrospective study.

5 mg100ug Lyophilized2 mg100 μg0.1 ml100ug100ug1 Set1 Set

Related Pathways

paperclip

#33038502   2020/10/07 To Up

A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.

Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα, β/δ and γ, play a central role in the regulation of glucose and lipid metabolism and of the inflammatory and fibrogenic pathways in liver and in other organs that all contribute to NASH pathogenesis. Lanifibranor (IVA337), a panPPAR agonist, by acting on these three different PPAR isotypes, combines pharmacological effects that could address the different components of the disease as demonstrated in preclinical models. Objectives NATIVE study (EudraCT: 2016-001979-70, NCT: NCT03008070) aims to assess the safety and the efficacy of a 24-week treatment with lanifibranor (800 and 1200 mg/day) in adult non-cirrhotic NASH patients. The primary efficacy endpoint is a 2-point reduction in the activity part of the Steatosis Activity Fibrosis (SAF) histological score (combining inflammation and ballooning) without worsening of fibrosis. Design NATIVE is a Phase 2b randomised, placebo-controlled, double-blind, parallel-assignment, dose-range study. Eligible adult patients with a confirmed histological diagnosis of NASH should have a SAF Activity score of 3 or 4 (>2) and a SAF Steatosis score ≥ 1. There is no specific criterion related to the fibrosis score except that patients with cirrhosis (F4) were excluded. Summary This study will evaluate the efficacy of a 24-week treatment of NASH with lanifibranor based on histological evaluations (SAF score) by biopsy. The number of responders according to the SAF Activity score-based definition from baseline to 24 weeks will be compared between groups and serves as primary endpoint.
Francque Sven, Bedossa Pierre, F Abdelmalek Manal, M Anstee Quentin, Bugianesi Elisabetta, Ratziu Vlad, Huot-Marchand Philippe, Scherrer Bruno, Junien Jean-Louis, Broqua Pierre, Abitbol Jean-Louis

1104 related Products with: A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.

11 mg

Related Pathways

paperclip

#33035234   2020/10/09 To Up

Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019.

A greater understanding of the antibody response to SARS-CoV-2 in an infected population is important for the development of a vaccination.
Ekasit Kowitdamrong, Thanyawee Puthanakit, Watsamon Jantarabenjakul, Eakachai Prompetchara, Pintip Suchartlikitwong, Opass Putcharoen, Nattiya Hirankarn

2511 related Products with: Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019.

100ug Lyophilized200ul500 tests 50 UG100 200ul1 mg200ul200ul

Related Pathways

paperclip

#33033172   // To Up

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.

We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with SARS-CoV-2 (of which 93% required hospitalization) up to 122 days after symptom onset and compared them to responses in 1548 individuals whose blood samples were obtained prior to the pandemic. After setting seropositivity thresholds for perfect specificity (100%), we estimated sensitivities of 95% for IgG, 90% for IgA, and 81% for IgM for detecting infected individuals between 15 and 28 days after symptom onset. While the median time to seroconversion was nearly 12 days across all three isotypes tested, IgA and IgM antibodies against RBD were short-lived with median times to seroreversion of 71 and 49 days after symptom onset. In contrast, anti-RBD IgG responses decayed slowly through 90 days with only 3 seropositive individuals seroreverting within this time period. IgG antibodies to SARS-CoV-2 RBD were strongly correlated with anti-S neutralizing antibody titers, which demonstrated little to no decrease over 75 days since symptom onset. We observed no cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies with other widely circulating coronaviruses (HKU1, 229 E, OC43, NL63). These data suggest that RBD-targeted antibodies are excellent markers of previous and recent infection, that differential isotype measurements can help distinguish between recent and older infections, and that IgG responses persist over the first few months after infection and are highly correlated with neutralizing antibodies.
Anita S Iyer, Forrest K Jones, Ariana Nodoushani, Meagan Kelly, Margaret Becker, Damien Slater, Rachel Mills, Erica Teng, Mohammad Kamruzzaman, Wilfredo F Garcia-Beltran, Michael Astudillo, Diane Yang, Tyler E Miller, Elizabeth Oliver, Stephanie Fischinger, Caroline Atyeo, A John Iafrate, Stephen B Calderwood, Stephen A Lauer, Jingyou Yu, Zhenfeng Li, Jared Feldman, Blake M Hauser, Timothy M Caradonna, John A Branda, Sarah E Turbett, Regina C LaRocque, Guillaume Mellon, Dan H Barouch, Aaron G Schmidt, Andrew S Azman, Galit Alter, Edward T Ryan, Jason B Harris, Richelle C Charles

1930 related Products with: Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.

100ug Lyophilized 100ul200ul100ug Lyophilized100ug Lyophilized100ug Lyophilized 100ul 100ul 100 UG200ul100ug Lyophilized 100ul

Related Pathways